Introduction
============

In Switzerland, more than 35\'000 joint arthroplasty procedures are performed every year to improve the quality of life of an aging population.[@B1] Prosthetic-joint infections (PJI) are rare, with an incidence of 1-2%, but they represent serious complications in terms of morbidity and costs.[@B2] For adequate care of a patient, the surgeon has to choose between different therapeutic options, of which surgery remains essential. If a replacement of the infected joint arthroplasty is needed, a success rate above 90% can be expected with a two-stage procedure.[@B2] Two-stage revision includes removal of all foreign material, debridement, and reimplantation of a new prosthesis after a variable period of time to manage the infection. Intravenous antimicrobial treatment is administered followed by oral therapy for a total of three months. Currently, there is no consensus regarding the optimal interval duration between the prosthesis explantation and reimplantation procedure. The interval varies from two weeks to several months \[Figure [1](#F1){ref-type="fig"}\].[@B2],[@B3]

The economic consequences associated with treating periprosthetic infections are known. Already in 1990, Sculco et al. demonstrated that the inadequate reimbursement of the treatment of prosthetic-joint infections causes an economic burden to the hospital and consequently to the healthcare system.[@B4],[@B5] In addition, between 1990 and 2004, a nearly two-fold increase in the incidence of these infections was observed in the United States.[@B6] The annual cost of infected revisions for US hospitals is projected to exceed 1.6 billion dollars by 2020.[@B7]

The Swiss Diagnosis Related Groups (SwissDRG; SDRG) tariff system for acute somatic inpatient hospital services was introduced in January 2012.[@B8] It consistently sets the remuneration of hospital services according to the latest revision of the Swiss Health Insurance law (LAMal) voted in 2007. The DRG system was invented as a patient classification system in 1967 by the scientists Robert Barclay Fetter and John Devereaux Thompson at the University of Yale. It was first implemented in 1983 in the USA to measure each individual patient\'s consumption of hospital resources.[@B5],[@B9],[@B10] Since then, DRGs have been introduced in many countries. SwissDRG is supposed to provide homogenous, transparent and comparable hospital remuneration, improve efficiency and reduce costs.[@B10] In it, each hospital stay is assigned to a group of pathologies, at the end of hospitalization, and reimbursed by the insurance companies at a fixed rate.[@B11] This form of remuneration compensates hospitals for cases, taken as a whole. Therefore, hospitals are not paid for each therapeutic act.[@B12] The groups include admissions for similar diagnoses with treatments costs supposed to be comparable. A software with a classification algorithm (grouper) allocates an inpatient admission in a SDRG. This allocation applies to several criteria, including the condition that has requested most of the resources (principal diagnosis) which does not always match the hospitalization pattern \[Figure [2](#F2){ref-type="fig"}\].[@B8] Today 974 SDRGs are defined.

The literature contains few economic evaluations of the revenues from the treatment of prosthetic-joint infections.[@B5],[@B13] This retrospective study intended to assess the economic impact of a two-stage exchange from a single-hospital perspective. We compared the revenues and the costs of each cases at the University Hospital of Lausanne in Switzerland from 2012, the year when the DRG system was introduced in Switzerland, to 2013.

Methods
=======

Patients
--------

The inclusion criteria were to have a two-stage exchange from January 2012 to December 2013, with a single stay at the University Hospital of Lausanne (CHUV) and a SDRG expected for a prosthetic-joint infection \[Table [1](#T1){ref-type="table"}\]. Patients with multiple stays (e.g. temporary transfer to a peripheral hospital) were excluded for sake of consistent comparison \[Figure [3](#F3){ref-type="fig"}\]. Patients with another SDRG (e.g. post-operative transplant) were excluded as well. Data for the included patients was extracted from electronic files and retrospectively analyzed using standard software (Microsoft Excel, IBM SPSS).

Revenues
--------

All economic data were obtained in Swiss francs (CHF) and converted to Euros (EUR), with an exchange rate of 1 CHF equivalent to 0.8545 EUR. The revenue is the remuneration obtained by the hospital for each hospital stay. Each SDRG has a number of points (cost-weight), according to the gravity of the group\'s pathologies \[Table [1](#T1){ref-type="table"}\]. The cost-weights are calculated measuring the cost for treatment of each SDRG in a sample of hospitals. They are adjusted annually**.** The base rate corresponds to the price of a SDRG point and is negotiated every year between each hospital and its insurance companies. The base rate was 10\'400 CHF (\~ 8\'886 EUR) in 2012 and 2013. The remuneration is obtained by multiplying the number of points (cost-weight) by the current price of the point (base rate) \[Figure [4](#F4){ref-type="fig"}\].[@B8]

For each SDRG, a \"normal\" length of hospital stay is defined. The cases in which the length of stay lays between the limits are qualified inliers. To minimize the economic incentive to refer a patient too soon, lengths of stays below the lower limit, called low-outliers, obtain a reduced remuneration. Conversely, remuneration of high-outliers, with a duration above the upper limit, is increased. Adjustments are done by increasing or decreasing the number of points (cost-weight) per day above or below the limits.

Costs
-----

The cost is the expense of the hospital for a hospital stay. We calculated the costs using a swiss standard approach named REKOLE (revision of cost accounting and charge capture).[@B14] It consists of a "top-down" cost-analysis where all the costs are attributed to the hospitals stays. In it, the annual costs directly generated by the patients (material, medication, medical fees, etc.) and the indirect costs which can not be exclusively imputed to the patients (administration, maintenance, etc.) are added. The sum of the costs is divided by all the hospital stays depending on the resources used. Thus, the cost of a hospital stay is calculated by documenting all the resources spent \[Table [2](#T2){ref-type="table"}\].

Results
=======

Patients
--------

37 prosthetic-joint infections were treated with a two-stage exchange in the Department of Septic Surgery at the University Hospital of Lausanne from 2012 to 2013. Six patients were excluded because they had multiple stays. 10 patients with another SDRG were also excluded. 21 patients were included \[Table [3](#T3){ref-type="table"}\].

Revenues
--------

The remuneration for inliers from 2012 to 2013 ranged from 26\'806 to 42\'978 CHF (\~ 22\'905-36\'723 EUR, median 36\'338 CHF, \~ 31\'049 EUR) depending on the SDRG, which is higher than similar studies.[@B13],[@B15] Meanwhile, our hospital stays were sometimes up to twice as long than the average length for each SDRG (especially in infections with difficult-to-treat microorganisms such as methicillin-resistant *S. epidermidis*) \[Table [3](#T3){ref-type="table"} and Figure [5](#F5){ref-type="fig"}\].

Costs
-----

The median total cost per patient was 76\'000 CHF (\~ 65\'000 EUR) (51\'151 to 118\'263; hip median 79\'744, knee median 66\'708), which is similar to costs found in other studies.[@B5]-[@B7] The overall costs allocation for the 21 patients is reported in Table [4](#T4){ref-type="table"}. More than two thirds of the costs came from the medical care and one third from the surgical procedure. The length of the hospital stay generated therefore the major part of the costs.

Comparison between costs and revenues
-------------------------------------

The revenues never covered all the costs, even with a short interval procedure (\< 4 weeks). The hospital lost a median of 35\'000 CHF per patient (\~ 30\'000 EUR) (22\'280 to 64\'666) \[Figure [6](#F6){ref-type="fig"}\]. As the length of stay seemed to be the most relevant parameter to act on, a simple linear regression was carried out to investigate its relationship to the costs. The scatterplot showed that there was a linear relationship between the two, which was confirmed with the simple linear regression (*p*-value = 0.012). The slope coefficient was -411 CHF so the deficit increases by 411 CHF (\~ 350 EUR) for each extra day of hospital stay \[Figure [7](#F7){ref-type="fig"}\]. The R^2^ value was 0.332 so 33.2% of the increase in the deficit can be explained by the model containing only the length of stay.

Discussion
==========

We observed that a main determinant of the costs was the length of stay. Several options could be considered to act on it. The innovative patient hotel concept, developed in Scandinavia in the 90s has proven to save money while maintaining high-quality care.[@B16]-[@B18] Already introduced in other DRG countries, the concept offers medical care in a private 3-stars hotel structure for patients who do not need to be on the acute inpatient ward but need to remain nearby the hospital for quick access to medical staff. This could be an interesting option between the explantation and the reimplantation in two-stage exchange to reduce the length of the hospital stay. It could also be possible to transfer temporally the patient to a rehabilitation hospital between the explantation and the reimplantation.

Another cost-saving potential would be to refer the patient back home with home caring and oral antibiotic therapy between the first and second stage of the surgical procedure. It has already been done in the German DRG system, on which the SwissDRG system is based.[@B13] With this solution, a new remuneration could be obtained with the second admission, in addition to decreasing the length of the hospital stay. According the SwissDRG system, the rehospitalization would have to take place after a period of 18 days in order to be considered as a new stay \[Figure [8](#F8){ref-type="fig"}\]. We compared the same costs and double revenues in a projection of the rehospitalization concept. The hospital would break even for our sample of patients (slope coefficient = 376 CHF, *p*-value = 0.05, R^2^ value = 0.214) \[Figure [9](#F9){ref-type="fig"}\].

It is also crucial to have more specific SDRGs for prosthetic-joint infections. The three SDRGs applied for treating prosthetic-joint infections include uncomplicated cases (e.g. revision without infection) and complicated cases (e.g. revision for infection). This causes a decrease in the length of the SDRG and thus in its ensuring revenues.[@B19] The German DRG system suggest to stratify more by the principal diagnosis than the surgical procedure.[@B13]

Our study has several limitations. Our research focused on the two first years after the introduction of the SDRG system because only these two had a complete cost-analysis yet from our accounting centers. These two years also had a same base rate making the analysis more consistent. The cost-weights and base rates might have been adjusted since then but there is no specific SDRGs for prosthetic-joint infections today making our conclusion still topical.

Moreover, our research was not designed to take into account the patient\'s insurance type (i.e. basic, semi-private, private). The only difference is that patients with semi-private or private insurances (N=5/21) consume more resources in medical fees and hotel charges. Hence, the costs could be biased and overrated.

Our conclusion is limited due to the single-hospital perspective with a small sample size which undermine the external validity of our study. We had to exclude patients with multiple stays or with another SDRG because we didn\'t have the costs from other hospitals accounting centers or the remuneration was not the proper one for a prosthetic-joint infection. There is a need of studies regarding the current economic impact in the healthcare system from a nationwide perspective. Additional research on prosthetic-joint infections is warranted using economic data, such as cost-effectiveness studies. It would be interesting to compare different interventions in treating prosthetic-joint infections to determine which one may best control infection and at the same time lower the economic burden.[@B20]

Conclusion
==========

In summary, this study showed that the current SDRG system may not be specific enough for rewarding prosthetic-joint infections as revenues never covered all the costs. University hospitals treating more prosthetic-joint infections than other hospitals could be disadvantaged since the introduction of the SDRG system.[@B19] These results coincide with other similar studies.[@B5],[@B13] Several options could be considered to act on the length of the hospital stay. It is also crucial that the SDRGs would be refined in order to reflect better the actual costs.
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###### 

SDRGs for prosthetic joint infections.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SDRG       Cost-weight     Definition
  ---------- --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  I03A\      2012 : 4.264\   Revision or replacement of the articulation of the hip with the diagnosis of complication or arthrodesis or age \< 16 years or bilateral interventions or multiple important interventions on the articulations of the legs with complex intervention, **with** extremely severe complications or malignant neoplasm
  (N=6/21)   2013 : 4.001    

  I03B\      2012 : 2.543\   Revision or replacement of the articulation of the hip with the diagnosis of complication or arthrodesis or age \< 16 years or bilateral interventions or multiple important interventions on the articulation of the legs with complex intervention, **without** extremely severe complications or malignant neoplasm
  (N=7/21)   2013 : 2.612    

  I04Z\      2012 : 2.776\   Revision or replacement of the articulation of the knee with the diagnosis of complication or arthrodesis
  (N=8/21)   2013 : 3.169    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Type of resources used.

  Surgical procedure              Cause of costs                                Cost
  ------------------------------- --------------------------------------------- ---------------------------------------
  Material and implants           Materiel and implants used                    Actual prices
  Operating theater               Operating theater staff time                  Duration of use x cost per min
  Anesthesia                      Anesthesiologist and nursing staff time       Duration of anesthesia x cost per min
  Blood                           Blood transfusions                            Actual prices
  Imagery                         Radiological tests                            Points x point value
  **Medical care**                                                              
  Medication                      Medication during whole stay                  Actual prices
  Medical fees and nursing        Doctors and nursing staff time                Time required x cost per min
  Hotel charges and food          Hotel charges and food                        Daily fee
  Intensive care unit             Treatment and nursing staff time              Time spent x cost per min
  Physiotherapy and ergotherapy   Physiotherapy and ergotherapy                 Points x point value
  Laboratory                      Laboratory tests                              Points x point value
  **Administration**                                                            
  Management                      Reception, accounting centers and archiving   Daily fee

###### 

Patient\'s demographic characteristics.

  Total patients 2012-2013                                                   21
  -------------------------------------------------------------------------- -------------
  Hip prosthesis                                                             13
  Knee prosthesis                                                            8
  Interval time (weeks, median and range)                                    3 (1.6-6.3)
  Length of stay (days, median and range depending on the infecting agent)   38 (27-70)
  *Staphylococcus aureus* (N=3)                                              42 (31-57)
  Coagulase-negative staphylococci (N=7)                                     38 (31-70)
  *Streptococcus* spp. (N=4)                                                 31 (28-63)
  Gram-negative rods (N=1)                                                   50
  *Cutibacterium acnes* (N=2)                                                39 (36-42)
  Culture-negative PJI (N=4)                                                 35 (27-39)
  Age (median and range)                                                     67 (56-88)
  Male                                                                       11
  Female                                                                     10

###### 

Costs allocation for the 21 patients.

  --------------------------------------------------------------------------------
  Surgical procedure (32%)    Medical care\                      Administration\
                              (67%)                              (1%)
  --------------------------- ---------------------------------- -----------------
  13% Material and implants   34% Medication and nursing         1% Management

  12% Operating theater       13% Medical fees                   

  3% Anesthesia               8% Hotel charges and food          

  3% Blood                    5% Intensive care unit             

  1% Imagery                  5% Physiotherapy and ergotherapy   

                              2% Laboratory                      
  --------------------------------------------------------------------------------
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